Menu
Back to Journals » Vascular Health and Risk Management » Volume 4 » Issue 6
Safety and efficacy of cilostazol in the management of intermittent claudication
Authors Chi Y, Lavie CJ, Milani RV, White CJ
Published 5 December 2008 Volume 2008:4(6) Pages 1197—1203
DOI https://doi.org/10.2147/VHRM.S3160
Review by Single anonymous peer review
Peer reviewer comments 5
Yung-Wei Chi, Carl J Lavie, Richard V Milani, Christopher J White
Department of Cardiology, Ochsner Clinic Foundation, New Orleans, LA, USA
Abstract: Peripheral arterial disease (PAD) is a major health problem affecting millions of patients worldwide. Many will suffer from intermittent claudication (IC), which leads to marked impairment of quality of life (QoL). Besides surgical and endovascular interventions to improve limb-specific outcomes, pharmacotherapy is an effective tool in the treatment of IC. Cilostazol, a Federal Drug Administration-approved medication for the treatment of IC, has demonstrated consistent efficacy in improving exercise capacity and overall health-related QoL. This manuscript will review the pharmacokinetics, safety, and efficacy of cilostazol in the treatment of patients with IC as well as compare this agent with other proven non-invasive therapies for PAD.
Keywords: peripheral arterial disease, cilostazol, intermittent claudication, supervised exercise therapy
© 2008 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.